Alector Inc Dossier
Qualitative Analysis
Business overview
Alector, Inc. (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies to counteract the progression of neurodegenerative diseases. The company applies principles from genetics, immunology, and neuroscience to design drug candidates intended to modify disease biology rather than only addressing symptoms. A central theme across Alector's programs is targeting mechanisms that remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Alector is also developing the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) technology designed to optimize the delivery of therapeutics (including antibodies, enzymes, and siRNA) broadly throughout the brain.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following clinical trial setbacks in late-stage partnered programs (latozinemab and nivisnebart), Alector has pivoted its core strategy to focus on its proprietary blood-brain barrier delivery platform, the Alector Brain Carrier (ABC). The platform is designed to enhance the delivery of antibodies, enzymes, and siRNA to the brain via peripheral dosing.
Expected impact: Enables the development of a highly differentiated, wholly owned preclinical and early-stage clinical pipeline targeting neurodegenerative diseases like Alzheimer's and Parkinson's with improved brain penetration and safety profiles.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to develop and commercialize AL008, a dual-function SIRP-alpha inhibitor and Fc gamma receptor activator antibody, for oncology indications in China.
Terms: Innovent leads development and commercialization in China. Alector is eligible to receive up to $11.5 million in development milestones, $112.5 million in sales milestones, plus future royalties on sales.